Article Text

Download PDFPDF
Drug-free inactive disease in juvenile idiopathic arthritis can be achieved for 40% of patients
  1. Laura Chapman1,
  2. Amanda J Friend1,2
  1. 1 School of Medicine, University of Leeds, Leeds, UK
  2. 2 Department of Paediatrics, Leeds General Infirmary, Leeds, UK
  1. Correspondence to Dr Amanda J Friend, Paediatrics, Leeds General Infirmary, Leeds LS1 3EX, UK; amanda.friend{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Study design: randomised, single-blind trial.

Study question

Setting: The Netherlands.1

Patients: 94 patients with new-onset (symptom duration <18 months) juvenile idiopathic arthritis (JIA) who had not been exposed to previous disease-modifying antirheumatic drug (DMARD) therapy.

Interventions: conventional systemic DMARD monotherapy (methotrexate (MTX) or sulfasalazine) versus MTX plus 6-week tapered course of prednisolone vs MTX plus etarnercept.

Outcomes: time to inactive disease; time to flare after the first episode of drug-free inactive disease (DFID).

Main results: …

View Full Text


  • Contributors LC: wrote the abstract. AJF and LC: jointly wrote the commentary.

  • Provenance and peer review Not commissioned; internally peer reviewed.